MLLCF News and Press, Molecular Partners AG From 05/27/21

Novartis (NVS) and Molecular Partners (MLLCF) have started the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of novel DARPin therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19.The EMPATHY trial is investigating the safety and efficacy of ensovibep in ea...

The first patient has been dosed in Molecular Partners' (MLLCF) Phase 2a clinical trial of ensovibep, a DARPin therapeutic candidate designed to bind to the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells.The single-arm study will enroll up to 40 patient...

Molecular Partners (MLLCF) and its collaborator Novartis (NVS) announced initial results from their ongoing phase 1 study of first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers. Healthy volunteers were randomized 3:1 to receive ensovibep or placebo, resp...

Molecular Partners (MLLCF) gained ~12.8% today after SVB Leerink gave the stock an outperform rating and lifted the price target to CHF 29 from CHF 27.The analyst Daina M. Graybosch notes the lower efficacy of monoclonal antibody therapies against the new COVID-19 variants that are ...

Molecular Partners (MLLCF) announces that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin therapeutic candidate for the treatment and prevention of COVID-19.MP0420 is designed to bind the receptor-binding domain of th...

Novartis (NVS) and Molecular Partners (MLLCF) announce a collaboration in the form of an option and license agreement to develop, manufacture and commercialize latter's anti-COVID-19 DARPin program, consisting of two therapeutic candidates, MP0420 and MP0423. MP0420 and MP0423 are potential m...

Molecular Partners ([[MLLCF]] +3.9%) has announced supportive preclinical data from in vivo assessments of its DARPin candidates targeting SARS-CoV-2.In the five-day experiment, all animals treated with DARPin molecules (MP0420 or MP0423) recovered and survived, while 83% of animals in t...

The following slide deck was published by Molecular Partners AG in conjunction with this Read more ...

Molecular Partners AG ( OTCPK:MLLCF ) : 1H GAAP EPS of -CHF1.14. More news on: Molecular Partners AG, Earnings news and commentary, Read more ...

AbbVie (NYSE: ABBV ) unit Allergan has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of DARPin drug abicipar pegol for the treatment of neovascular age-related macular degeneration (wet AMD). More news on: AbbVie Inc., Molecul...